HMG-CoA reductase inhibitor decreases small dense low-density lipoprotein and remnant-like particle cholesterol in patients with type-2 diabetes.

[1]  M. Adachi,et al.  High prevalence of small dense LDL in diabetic nephropathy is not directly associated with kidney damage: a possible role of postprandial lipemia. , 1998, Atherosclerosis.

[2]  J. Hendriks,et al.  Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[3]  M. Kitahara,et al.  Hypolipidemic effect of NK-104, a potent HMG-CoA reductase inhibitor, in guinea pigs. , 1999, Atherosclerosis.

[4]  T. Taniguchi,et al.  Elevated remnant-like lipoprotein particles in impaired glucose tolerance and type 2 diabetic patients. , 1999, Diabetes care.

[5]  H Yasue,et al.  Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. , 1999, Circulation.

[6]  R. Krauss,et al.  Identification of multiple subclasses of plasma low density lipoproteins in normal humans. , 1982, Journal of lipid research.

[7]  W A Hsueh,et al.  Cardiovascular risk continuum: implications of insulin resistance and diabetes. , 1998, The American journal of medicine.

[8]  K. Tan,et al.  Roles of hepatic lipase and cholesteryl ester transfer protein in determining low density lipoprotein subfraction distribution in Chinese patients with non-insulin-dependent diabetes mellitus. , 1999, Atherosclerosis.

[9]  M. Tremblay,et al.  Plasma remnant-like particle lipid and apolipoprotein levels in normolipidemic and hyperlipidemic subjects. , 1998, Atherosclerosis.

[10]  K. Nakajima,et al.  Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels. , 1993, Clinica chimica acta; international journal of clinical chemistry.

[11]  N. Hoogerbrugge,et al.  Atorvastatin increases low-density lipoprotein size and enhances high-density lipoprotein cholesterol concentration in male, but not in female patients with familial hypercholesterolemia. , 1999, Atherosclerosis.

[12]  G. Dallinga-Thie,et al.  High Dose of Simvastatin Normalizes Postprandial Remnant-Like Particle Response in Patients With Heterozygous Familial Hypercholesterolemia , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[13]  G. Yoshino,et al.  Low density lipoprotein particle diameter in young, nonobese, normolipidemic Japanese men. , 1999, Atherosclerosis.

[14]  M. Laakso,et al.  Relationship of LDL size to insulin sensitivity in normoglycemic men. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[15]  R. Krauss,et al.  Greater oxidative susceptibility of the surface monolayer in small dense LDL may contribute to differences in copper-induced oxidation among LDL density subfractions. , 1995, Journal of lipid research.

[16]  M. Austin,et al.  Small, dense low density lipoproteins, the insulin resistance syndrome and noninsulin-dependent diabetes , 1996, Current opinion in lipidology.

[17]  K. Nakajima,et al.  Effect of bezafibrate or pravastatin on serum lipid levels and albuminuria in NIDDM patients. , 2000, Journal of atherosclerosis and thrombosis.

[18]  A. Slyper,et al.  Low-density lipoprotein density and atherosclerosis. Unraveling the connection. , 1994, JAMA.

[19]  C. Packard,et al.  Atherogenic lipoprotein phenotype in Type 2 diabetes: reversal with micronised fenofibrate , 1999, Diabetes/metabolism research and reviews.

[20]  S. Koba,et al.  Small Dense Low-Density Lipoprotein in Japanese Men with Coronary Artery Disease , 2000, Annals of Internal Medicine.

[21]  M. Kitahara,et al.  Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. , 1997, Arzneimittel-Forschung.

[22]  R. Krauss,et al.  Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. , 1996, JAMA.

[23]  E. Levy,et al.  Apoprotein B structure and receptor recognition of triglyceride-rich low density lipoprotein (LDL) is modified in small LDL but not in triglyceride-rich LDL of normal size. , 1994, The Journal of biological chemistry.

[24]  A. de Leiva,et al.  Optimization of Glycemic Control by Insulin Therapy Decreases the Proportion of Small Dense LDL Particles in Diabetic Patients , 1997, Diabetes.

[25]  J. Keul,et al.  Influence of 4 weeks' intervention by exercise and diet on low-density lipoprotein subfractions in obese men with type 2 diabetes. , 1999, Metabolism: clinical and experimental.

[26]  R. Krauss,et al.  LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[27]  S. Grundy,et al.  Remnant-like particle cholesterol levels in patients with dysbetalipoproteinemia or coronary artery disease. , 1998, The American journal of medicine.

[28]  H. Masuoka,et al.  Association of remnant-like particle cholesterol with coronary artery disease in patients with normal total cholesterol levels. , 2000, American heart journal.

[29]  P. Wilson,et al.  Lipoproteins, apolipoproteins, and low-density lipoprotein size among diabetics in the Framingham offspring study. , 1996, Metabolism: clinical and experimental.

[30]  A. Catapano,et al.  NK-104, a potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, decreases apolipoprotein B-100 secretion from Hep G2 cells. , 1999, Atherosclerosis.